Current Position:  Home About Us

About Us

关于我们

The group consists of six companies in China, the United States and Australia, focusing on the development of innovative immunotherapy drugs for malignant tumors and inflammatory diseases. One of its scientists, Professor Liu Yang, is an internationally renowned immunologist and a fellow of the American Association for the Advancement of Science. With the rapid rise of innovative drugs in China, Liu Yang and his partners established Guangzhou Acolmmune Biopharma Co., LTD in 2018. In March 2022, Guangzhou Acolmmune Biopharma Co., Ltd. signed a contract with Jiangning High-tech Zone to establish Nanjing Acolmmune Biopharma Co., LTD., which will serve as China's R & D center and future industrialization base. It is committed to developing innovative immunotherapy drugs, focusing on the immunotherapy of malignant tumors and inflammatory diseases, and bringing more treatment means to clinical patients.

Nanjing Acolmmune Biopharma Co., Ltd. is located in Ruihong Cell and gene Industrial Park, using a total of 6000 square meters of three-storey plant to build a research and development center and pilot workshop to speed up the development and approval process of innovative drug products.

In March 2024, the Innovation center for macromolecular drugs and the Innovation Center for Immunoantibody Coupling drugs were unveiled in Jiangning High-tech Zone, Nanjing. The research and development laboratory, pilot workshop and quality control laboratory were newly renovated. R&d personnel have been stationed and started project experiments, and a number of products are currently under research.

Nanjing Acolmmune
Biopharma Co., LTD

Establishment
Address
President
Business scope

April 20, 2022
Floor 6-8, Building 6, Ruihong Cell and Gene Industrialization, Jiangning District, China
Liu Yang
Pharmaceutical production and related research and development

Regional planning
6F-Pilot production area
7F-PD Development / QC Lab
8F-Early research laboratory

Including antibody workshop, CAR T cell therapy workshop, process development laboratory, analytical laboratory, etc

Floor Area

6,270

㎡

6-8 layers to meet the needs of different types of product development and pilot testing

Cumulative Input

280m

A total of 180 million yuan has been invested in research and development, and about 100 million yuan has been invested in pilot projects

Drug discovery

Conduct in-depth basic research at the cellular and molecular level, and explore possible drug targets and forms from the disease mechanism.

Cell construction

Based on the in-depth understanding of the cell, the cell is used as a carrier for drug preparation or to enhance the function of a specific cell.

Process development

Various engineering techniques are used to make the drug preparation have clinical application value and achieve safe and effective accessibility.

Pilot production

Based on the application of the principle of drug preparation technology, the laboratory drug technology was scaled up to the clinical application scale.

Analysis and detection

Advanced mass spectrometry, high performance liquid phase, flow cytometry and capillary electrophoresis were used to analyze and monitor the drug properties.

Through the establishment of five major platforms of drug discovery, cell construction, process development, pilot production, analysis and testing, the end-to-end industry-universal-research transformation from basic science research to commercial manufacturing is formed, and various innovative drugs such as antibodies (mAb/BsAb), CAR T cells, and antibody derivatives (ADC/TCEs) are incubated.

The company will always be committed to developing innovative immunotherapy drugs, focusing on the immunotherapy of malignant tumors and inflammatory diseases,
to bring more best-in-class/best-in-class products to clinical patients

Antibody /ADC area

Covering CTLA-4 and CD24 targets, focus on drug development, production and sales of the best/first of its kind products in the field of immunotherapy

Cell therapy

Take solid tumors as a breakthrough, and bring more new treatment methods to patients

Commercial production

Planning commercial production, layout of global drug production foundry